Wnt to market

How Samumed and its investors justify its $12 billion private valuation

With no traditional life science VCs in its syndicate and little publicly disclosed about its science, Samumed LLC was able to raise a $438 million round at a premoney valuation of $12 billion, bringing its total funding to more than $650 million to date.

The company hasn’t yet described any of its Wnt signaling pathway modulators’ mechanisms or targets, but

Read the full 590 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE